Treatment of Thrombosis in Antiphospholipid Syndrome

Guillermo Ruiz-Irastorza; Munther Khamashta

doi:10.1016/B978-0-444-63655-3.00016-8

Treatment of Thrombosis in Antiphospholipid Syndrome

Guillermo Ruiz-Irastorza, Munther Khamashta

Women & Children's Health

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Thromboses are among the most severe manifestations of antiphospholipid syndrome (APS), particularly those affecting cerebral arteries. Thus, correct management of thrombotic complications is paramount to improving the prognosis of patients with antiphospholipid antibodies (aPL). In fact, the ideal approach would be to prevent patients with aPL from developing full APS (ie, to keep them asymptomatic). Unfortunately, on many occasions, the clinical event comes first, and it is then that we notice the presence of aPL. We all agree that whatever the clinical scenario – patients with thrombosis or asymptomatic aPL carriers – every effort must be made to prevent clotting events. However, the optimal treatment regimes are sometimes a matter of intense debate.

Original language	English
Title of host publication	Handbook of Systemic Autoimmune Diseases
Publisher	Elsevier Ltd
Pages	231-241
Number of pages	11
DOIs	https://doi.org/10.1016/B978-0-444-63655-3.00016-8
Publication status	Published - 1 Jan 2017

Publication series

Name	Handbook of Systemic Autoimmune Diseases
Volume	12
ISSN (Print)	1571-5078

Keywords

anticoagulants
antiphospholipid antibodies
Antiphospholipid syndrome
thrombosis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/B978-0-444-63655-3.00016-8

Cite this

@inbook{81634b54ed824c9d942941964fcbea21,

title = "Treatment of Thrombosis in Antiphospholipid Syndrome",

abstract = "Thromboses are among the most severe manifestations of antiphospholipid syndrome (APS), particularly those affecting cerebral arteries. Thus, correct management of thrombotic complications is paramount to improving the prognosis of patients with antiphospholipid antibodies (aPL). In fact, the ideal approach would be to prevent patients with aPL from developing full APS (ie, to keep them asymptomatic). Unfortunately, on many occasions, the clinical event comes first, and it is then that we notice the presence of aPL. We all agree that whatever the clinical scenario – patients with thrombosis or asymptomatic aPL carriers – every effort must be made to prevent clotting events. However, the optimal treatment regimes are sometimes a matter of intense debate.",

keywords = "anticoagulants, antiphospholipid antibodies, Antiphospholipid syndrome, thrombosis",

author = "Guillermo Ruiz-Irastorza and Munther Khamashta",

year = "2017",

month = jan,

day = "1",

doi = "10.1016/B978-0-444-63655-3.00016-8",

language = "English",

series = "Handbook of Systemic Autoimmune Diseases",

publisher = "Elsevier Ltd",

pages = "231--241",

booktitle = "Handbook of Systemic Autoimmune Diseases",

address = "United Kingdom",

}

TY - CHAP

T1 - Treatment of Thrombosis in Antiphospholipid Syndrome

AU - Ruiz-Irastorza, Guillermo

AU - Khamashta, Munther

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Thromboses are among the most severe manifestations of antiphospholipid syndrome (APS), particularly those affecting cerebral arteries. Thus, correct management of thrombotic complications is paramount to improving the prognosis of patients with antiphospholipid antibodies (aPL). In fact, the ideal approach would be to prevent patients with aPL from developing full APS (ie, to keep them asymptomatic). Unfortunately, on many occasions, the clinical event comes first, and it is then that we notice the presence of aPL. We all agree that whatever the clinical scenario – patients with thrombosis or asymptomatic aPL carriers – every effort must be made to prevent clotting events. However, the optimal treatment regimes are sometimes a matter of intense debate.

AB - Thromboses are among the most severe manifestations of antiphospholipid syndrome (APS), particularly those affecting cerebral arteries. Thus, correct management of thrombotic complications is paramount to improving the prognosis of patients with antiphospholipid antibodies (aPL). In fact, the ideal approach would be to prevent patients with aPL from developing full APS (ie, to keep them asymptomatic). Unfortunately, on many occasions, the clinical event comes first, and it is then that we notice the presence of aPL. We all agree that whatever the clinical scenario – patients with thrombosis or asymptomatic aPL carriers – every effort must be made to prevent clotting events. However, the optimal treatment regimes are sometimes a matter of intense debate.

KW - anticoagulants

KW - antiphospholipid antibodies

KW - Antiphospholipid syndrome

KW - thrombosis

UR - http://www.scopus.com/inward/record.url?scp=85045917408&partnerID=8YFLogxK

U2 - 10.1016/B978-0-444-63655-3.00016-8

DO - 10.1016/B978-0-444-63655-3.00016-8

M3 - Chapter

AN - SCOPUS:85045917408

T3 - Handbook of Systemic Autoimmune Diseases

SP - 231

EP - 241

BT - Handbook of Systemic Autoimmune Diseases

PB - Elsevier Ltd

ER -

Treatment of Thrombosis in Antiphospholipid Syndrome

Abstract

Publication series

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this